Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors

  Infinity Appoints Two Experienced Life Science Leaders to Its Board of

Business Wire

CAMBRIDGE, Mass. -- March 11, 2014

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has
appointed José Baselga M.D., Ph.D. and Jeff Berkowitz as independent members
of its board of directors. Dr. Baselga, physician-in-chief at Memorial Sloan
Kettering Cancer Center, is an accomplished clinician and a thought leader in
the PI3K field. Mr. Berkowitz, as the President of Walgreens Boots Alliance
Development, GmbH (WAG) in Europe, has a wealth of experience in
pharmaceuticals, pharmacy, distribution and market access, pricing and

“We are delighted to add José and Jeff to our board of directors. José’s
tremendous knowledge and expertise in the area of oncology drug discovery and
development is a great asset, which will be important as ^ we move our
pipeline forward through the clinical and regulatory process. Jeff brings a
wealth of experience with the changing world of global reimbursement, together
with US and European regulatory and commercial dynamics,” said Adelene Q.
Perkins, chair and chief executive officer of Infinity. “With IPI-145 in Phase
3 development, José and Jeff are ideal additions to our board, and we look
forward to their contributions as we build Infinity.”

“It’s an exciting time to join Infinity’s board of directors, and I look
forward to working with the team,” stated Dr. Baselga. “With a continued focus
on breakthrough science and a maturing pipeline targeting hematologic
malignancies and inflammatory conditions, Infinity is well positioned to
deliver important new medicines to patients.”

Mr. Berkowitz added, “I’m thrilled to join Infinity’s board at this stage in
the company's development. With a broadly active investigational drug in
IPI-145, and an experienced team, I believe that Infinity has the elements in
place to become a fully integrated biotechnology company.”

Infinity also announced today that Thomas Lynch, M.D. and Martin Babler have
retired from the board. Dr. Lynch and Mr. Babler were important contributors
as Infinity built its initial clinical organization and developed early market
insights that informed the company’s clinical development strategies. “We are
most appreciative of the great counsel Tom and Matt provided at critical
junctures in the company’s history,” said Adelene Q. Perkins. “We look forward
to carrying their insights forward as we work to bring IPI-145 to patients
with hematologic malignancies and debilitating inflammatory conditions.”

Dr. Baselga has served as Physician-in-Chief at Memorial Sloan-Kettering
Cancer Center since January 2013. He was formerly Chief and Bruce A. Chabner
Chair of the Division of Hematology/Oncology at Massachusetts General Hospital
(MGH), Associate Director of the MGH Cancer Center, and Professor of Medicine
at Harvard Medical School. Dr. Baselga was also Associate Director of Clinical
Services at Dana-Farber/Harvard Cancer Center. From 1996-2010, Dr. Baselga was
chairman of the Medical Oncology Service and director of the Division of
Medical Oncology, Hematology and Radiation Oncology at the Vall d'Hebron
Institute of Oncology in Barcelona, Spain. Dr. Baselga was previously the
president of the European Society of Medical Oncology and served on the board
of directors of the American Society of Clinical Oncology (ASCO). He is
currently a member of the board of directors of the American Association for
Cancer Research (AACR) and was the Chairman of the 2013 AACR annual meeting.

Dr. Baselga received his medical degree from the Universidad Autonoma of
Barcelona in 1982. He did his Internal Medicine Residency at both Vall
d'Hebron University Hospital in Barcelona, Spain and the State University of
New York in the US. He completed a fellowship in Medical Oncology at Memorial
Sloan Kettering Cancer Center in New York. Dr. Baselga has published more than
300 peer-reviewed articles and 400 abstracts and book chapters in his career.

Mr. Jeffrey Berkowitz is President of Walgreens Boots Alliance Development
GmbH and is Senior Vice President of Pharmaceutical Development and Market
Access of Walgreen Co. As part of Walgreens’ strategic partnership with
Alliance Boots, Mr. Berkowitz is responsible for the creation and development
of a new joint venture company based in Europe. Mr. Berkowitz and his team
lead all of Walgreens’ relations with branded and generic pharmaceutical
manufacturers and related development programs worldwide, and also oversee
Walgreens North American-based purchasing and branded pharmaceutical
relationships. As the senior-most Walgreens executive residing outside of the
U.S., Berkowitz leads the global health and wellbeing efforts on the ground
overseas. Prior to joining Walgreens in September 2010, Berkowitz was senior
vice president of global market access for Merck & Company, Inc. In that role,
he was accountable for all activity related to access, pricing, payer
marketing, health outcomes and health technology assessments worldwide and a
member of the Global Human Health and Emerging Markets leadership teams. From
2002 to 2009, Berkowitz held a variety of positions with increasing
responsibility in market access, sales and marketing with Schering-Plough
prior to its acquisition by Merck in 2009. Berkowitz earned his bachelor’s
degree in political science from Union College in Schenectady, N.Y., and his
Juris Doctor from Brooklyn Law School in Brooklyn, N.Y. He has been recognized
three times in PharmaVoice magazine as one of the 100 Most Inspiring Leaders
in the Life Sciences in 2009, 2010 and 2012.

About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to discovering,
developing and delivering best-in-class medicines to people with
difficult-to-treat diseases. Infinity combines proven scientific expertise
with a passion for developing novel small molecule drugs that target emerging
disease pathways. For more information on Infinity, please refer to the
company’s website at

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include those regarding the company’s expectations about its
ability to execute on its plans and strategies; and the therapeutic potential
of IPI-145 and PI3K inhibition. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual events or
results to differ materially from the company’s current expectations. For
example, there can be no guarantee that Infinity will initiate clinical trials
or report data in the time frames it has estimated, that any product candidate
Infinity is developing will successfully complete necessary preclinical and
clinical development phases or that development of any of Infinity’s product
candidates will continue. Further, there can be no guarantee that any positive
developments in Infinity’s product portfolio will result in stock price
appreciation. Management’s expectations and, therefore, any forward-looking
statements in this press release could also be affected by risks and
uncertainties relating to a number of other factors, including those risks
described in greater detail under the caption “Risk Factors” included in
Infinity’s annual report on Form 10-K filed with the Securities and Exchange
Commission (SEC) on February 25, 2014, and other filings filed by Infinity
with the SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof, and Infinity expressly disclaims any
obligation to update any forward-looking statements, whether as a result of
new information, future events or otherwise.


Infinity Pharmaceuticals, Inc.
Kate Murray, +1-617-910-8910
Press spacebar to pause and continue. Press esc to stop.